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Background/aim: The purpose of this study was to investigate proliferation and differentiation markers in colorectal adenocarcinoma
and their correlation with clinicopathological factors.
Materials and methods: Samples were collected from 38 patients with colorectal adenocarcinoma and 10 healthy controls. E-cadherin,
carcinoembryonic antigen (mCEA), cyclin B1, vascular endothelial growth factor (VEGF), and erythropoietin (EPO) receptor (EPOR)
were examined by immunohistochemistry; VEGF and EPO were examined by real-time PCR.
Results: The tumor samples were mostly characterized by large dimension (pT3), moderate level of differentiation (G2), negative lymph
node status (N0), and no metastasis. Cyclin B1 and VEGF gene and protein expressions were significantly higher in tumor tissues than
in control tissues; E-cadherin expression was significantly decreased in tumor samples and in positive correlation with mCEA. EPO was
almost undetectable in tumor tissues of colorectal adenocarcinoma. Significant positive correlation was detected between tumor size
and cyclin B1, tumor grade, and lymph node status.
Conclusion: Decreased expression of EPO, high levels of VEGF and cyclin B1 expression, predominant moderate tumor differentiation,
absence of metastasis, and negative lymph node status may suggest low level of aggressiveness, better prognosis, and longer patient
survival.
Key words: Adenocarcinoma of colon, E-cadherin, mCEA, cyclin B1, erythropoietin receptor, vascular endothelial growth factor,
erythropoietin

1. Introduction
Colorectal cancer is the second most prevalent malignancy
in Europe (1). In 2013 in Serbia the estimated new cases
of colorectal cancer were 3900, making it the second
most frequent malignant tumor in the country (2). The
expression of E-cadherin, carcinoembryonic antigen
(mCEA), cyclin B1, erythropoietin (EPO), EPO receptor
(EPOR), and vascular endothelial growth factor (VEGF)
indicate the presence, extent, and response to therapy of
this neoplasm and define the survival period (3,4). mCEA
is one of the most extensively studied tumor markers in
colon cancers. During the early stage of colorectal cancer
mCEA has a low sensitivity and expression; it becomes
more prominent during the process of tumor development
(4). E-cadherin belongs to a family of transmembrane
glycoproteins involved in the mediation of calciumdependent cell-cell adhesion in epithelial tissues (5).
* Correspondence: oliveram@imi.bg.ac.rs
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Previous studies have shown a fundamental association
between downregulation of E-cadherin expression in
tumor cells and the progression of an invasive tumor
(6). According to previous results, there is a negative
correlation between the level of E-cadherin expression and
tumor grade (7–9).
EPOR is highly expressed in endothelial cells, neurons,
the uterus, and various solid tumors (10). EPO and EPOR
have a significant role in the process of neoangiogenesis,
stimulating survival of hypoxic cancer cells and tumor
growth (11). It has been shown that EPO and EPOR
expressions are more prominent in adenocarcinoma of the
colon than in mucinous carcinomas; they are also more
prominent in moderately differentiated carcinomas than
in poorly differentiated ones (12,13). Besides EPO and
EPOR, VEGF is considered one of the most important
angiogenic agents overexpressed in colon adenocarcinoma
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(14). In addition to tumor tissues, VEGF is expressed in
noncancerous colonic tissue (14,15).
Cyclin B1 belongs to the cyclin family of proteins
involved in the control of normal cell proliferation (16).
Cyclin B1 is the component of the maturation/mitosispromoting factor with an important role in the G2–M
transition (16,17). Cyclin B1 expression is irregular with
minimal expression in the G1 phase, and maximal at the
G2–M transition, which results in early entry into mitosis,
uncontrolled cell proliferation, and tumor growth (16,17).
Previous studies reported that cyclin B1 was detected in
breast, prostate, colon, and oral cancers; high levels of its
expression are associated with poor survival of patients
(18,19).
The aim of our study was to investigate the
immunohistochemical expression of E-cadherin, mCEA,
cyclin B1, VEGF, EPO, and EPOR in adenocarcinoma of the
colon and their correlation with basic clinicopathological
characteristics. In addition to protein studies of angiogenic
factors EPOR and VEGF, we also performed their
gene expression studies concomitantly in cancer and
neighboring healthy tissues. Using this approach, we
wanted to shed light on the proliferation, differentiation,
and angiogenesis markers in adenocarcinoma of the colon
as potential diagnostic and prognostic factors.
2. Materials and methods
2.1. Subjects
The present study was performed in accordance with the
regulations of the local ethics committee. We included
38 patients with adenocarcinoma of the colon who
underwent surgery. We also included 10 controls for
immunohistochemistry and 38 control samples for RTPCR.
2.2. Immunohistochemical procedure
The examined tumor tissue specimens were fixed in
10% buffered (PBS) formalin and embedded in paraffin.
Tissue blocks of the tumor (five tissue sections of each
paraffin block) were transversely cut in 5-µm-thick
serial sections. Five consecutive sections from each
level, taken at intervals of 20–50 µm, were stained with
different antibodies. For immunohistochemical analysis,
polyclonal and monoclonal antibodies against mCEA
(monoclonal mouse anti-human antibody, Novocastra,
Leica Biosystems Ltd, Clone: 12–140-10), E-cadherin
(monoclonal mouse anti-human antibody, Dako, LOT
NO: 00023), cyclin B1 (monoclonal mouse anti-human
antibody, Dako, LOT NO: 098), EPOR (rabbit polyclonal
anti-mouse antibody, Santa Cruz Biotechnology, LOT NO:
D1210), VEGF (BD Pharmingen, cat. no. 555036, dilution
1:1000) were used. The tissue samples were fixed in 10%
buffered formalin solution and embedded in paraffin. The
tissue sections were cut at 5 µm, heated at 56 °C for 60

min, then deparaffinized and rehydrated through a series
of xylenes and alcohols, followed by an epitope retrieval
step. Tissue sections were treated with 3% H2O2 solution in
PBS to block endogenous peroxidase activity. Then tissue
sections of colon cancer and control tissues were heated
in a microwave oven (at 680 W, in 10 mmol/L citrate
buffer with a pH of 6.0 for 21 min) for epitope retrieval.
The next step was incubation of tissue sections with
appropriate antibodies (against mCEA, E-cadherin, cyclin
B1, VEGF, and EPOR) in a humid chamber for 60 min
at room temperature. Immunostaining was performed
using the streptavidin–biotin technique (LSAB+/HRP
Kit, Peroxidase Labeling, K0690, DakoCytomation). The
immunoreactivity complex was visualized with Dako
Liquid DAB + Substrate/Chromogen System (Code No.
K 3468) and counterstained with Mayer’s hematoxylin
(Merck). Tumor tissue sections with omitted primary
antibody were used as negative controls. Tumor tissue
sections known to express mCEA, E-cadherin, cyclin
B1, and EPOR were used as positive controls for
immunohistochemical staining.
2.3. Scoring system
EPOR and mCEA expressions of 0 and 2 grades and
E-cadherin expression of 0 and 1 grades were considered
negative expression, while in other cases the expression
of those three markers was considered positive. Tissue
samples for EPOR, mCEA, and E-cadherin were scored on
a scale representing the estimated proportion and intensity
of positive-staining tumor cells (with a range of 0–6). The
scores for EPOR, mCEA, and E-cadherin were determined
by adding intensity for the immunoreactivity staining
of tumor cells (0, none; 1, weak; 2, intermediate; and 3,
strong) and the average number of staining tumor cells. The
number of cyclin B1 immunoreactive cells was determined
in the surface and glandular epithelium using a computersupported imaging system connected to a light microscope
(Olympus AX70) with objective magnification of 40×. The
intensity of the cyclin B1 immunostaining was evaluated
by dividing staining reactions in three score groups: 0:
no immunostaining cells; 1: weak to moderate staining
intensity in 1% to 50% of tumor cells; 2: strong staining
intensity in >50% of tumor cells. Immunoreactivity for
VEGF expression was evaluated according to the degree of
staining, with staining intensities scored as: 0, no positive
staining cells; 1, less than 10% of cells stained; 2, 11% to
50% of cells stained; 3, more than 50% of cells stained.
The group of patients with positive VEGF expression was
defined by observation of staining of more than 10% of the
tumor area (scores 2 and 3).
2.4. Real-time PCR
We used the RNeasy protocol for the isolation of total
RNA from 38 tumors and 38 healthy tissues according
to the manufacturer’s instructions (Qiagen GmbH).
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Concentration and integrity of total RNA was assessed
using Ultrospec 3300 spectrophotometer (Amersham
Pharmacia). Equal amounts of RNA from different
samples were transcribed into cDNA using the Maxima
First Strand cDNA Synthesis kit (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Quantitative
real-time PCR analyses were performed using a 4800 Light
Cycler (Roche) and Taqman oligonucleotides probes for
VEGF. The oligonucleotides probe 5’ CCA AGT GGT
CCC AGG CTG CAC C 3’ was fluorescently labeled on
the 5’ end with 6-carboxy-fluorescein and on the 3` end
with 6-carboxy-tetramethyl-rhodamine. VEGF primers
were: forward 5’ TTG CTG CTC TAC CTC CAC CAT 3’
and reverse 5’ CAC TTC GTG ATG ATT CTG CCC 3’.
PCR reaction conditions consisted of 50 °C for 2 min and
95 °C for 4 min, followed by cycling between a melting
temperature of 95 °C for 15 s and an anneal-extension
temperature of 60 °C for 1 min, repeated for 40 cycles.
Quantification of the corresponding mRNA transcript
was determined by comparison with VEGF specific cDNA
standards. β-Actin was used as an internal control for the
total amount of RNA analyzed.
2.5. Statistical analysis
The results are expressed as means ± standard deviation
(SD). Values were compared using independent samples
t-tests with SPSS 19 for Windows. P < 0.05 was considered
significant.
3. Results
3.1. Clinicopathological parameters and correlation with
biological markers
The ages of patients ranged from 54 to 86 years (mean
± SD, 72.8 ± 8 years). The tumor size ranged between 1.5
and 10 cm, and the histological grades were G1, G2, and
G3 in 18.4% (7/38), 76.3% (29/38), and 5.3% (2/38) of
patients, respectively. In 23 patients (60.6%) lymph node
status was negative, while positive lymph node status was
detected in 15 patients (39.4%). Distant metastasis was
found in only 1 (2.6%) patient (Table 1). Statistical analyses
showed a significant positive correlation between tumor
size and positive lymph node status (r = 0.483, P < 0.01),
and between tumor size and histological tumor grade (r
= 0.342, P < 0.05, Table 2). Significant positive correlation
was also found between tumor size and cyclin B1 tumor
expression (r = 0.414, P < 0.01, Table 2) and between
E-cadherin and mCEA expression (r = 0.409, P < 0.05,
Table 2). Significant negative correlation was detected
between VEGF protein expression and lymph node status
(r = –0.329, P < 0.05, Table 2).
3.2. E-cadherin, mCEA, and cyclin B1 immunoexpression
Positive E-cadherin protein expression in tumors was
detected in 30 patients (78.9%) and in all 10 controls
(10/10, 100%, Table 3). In our study group the highest
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Table 1. Clinicopathological characteristic of adenocarcinoma of
the colon.
Clinicopathological
parameters

Adenocarcinoma of the colon

Tumor size
pTx

0

pT0

0

pT1

4 (10.5%)

pT2

6 (15.8%)

pT3

26 (68.4%)

pT4

2 (5.3%)

Unknown

0

Histological grade
G1

7 (18.4%)

G2

29 (76.3%)

G3

2 (5.3%)

Unknown

0

Lymph node status
Nx

0

N0

23 (60.6%)

N1

11 (28.9%)

N2

4 (10.5%)

N3

0

Unknown

0

Metastasis
Mx

0

M0

37 (97.4%)

M1

1 (2.6%)

Unknown

0

level of E-cadherin expression, with scores of 5 and 6, was
detected in 17 patients (17/38, 44.7%, Table 3); moderate
level of expression (4) was found in 9 (9/38, 23.7%)
patients; and low level of expression (3) was detected in 4
patients (4/38, 10.5%, Table 3). Statistical analysis showed
significant differences in E-cadherin expression between
tumor and control samples (F = 4.257, P < 0.05, Figure 1).
High level of positive expression (5 and 6) for mCEA was
detected in 29 patients (29/38, 76.3%), while minimum
level of positive expression was detected in 3 patients

MITROVIĆ AJTIĆ et al. / Turk J Med Sci
Table 2. Correlation between E-cadherin, mCEA, EPOR, cyclin B1, VEGF gene and VEGF protein expressions, and clinicopathological
characteristics.
E-cadherin

mCEA

Cyclin B1

EPOR

VEGF
gene

VEGF
IHC

Tumor
size

Lymph
node status

Grade

Metastasis

Age

E-cadherin

1

0.409*

–0.195

–0.062

–0.112

–0.118

–0.078

–0.203

0.164

–0.038

–0.184

mCEA

0.409*

1

–0.115

0.041

–0.071

–0.231

0.000

0.000

0.111

–0.211

0.049

Cyclin B1

–0.195

–0.115

1

–0.034

0.054

–0.071

0.414**

0.191

0.275

0.247

–0.048

EPOR

–0.062

0.041

–0.034

1

–0.164

–0.195

–0.107

–0.056

–0.291

0.077

0.201

VEGF gene

–0.112

–0.071

0.054

–0.164

1

–0.245

–0.245

–0.079

0.019

0.142

0.003

VEGF IHC

–0.118

–0.231

–0.071

–0.195

–0.245

1

–0.180

–0.33*

–0.085

0.108

–0.081

Tumor size

–0.078

0.000

0.414**

–0.107

–0.245

–0.180

1

0.483**

0.342*

0.098

–0.053

Lymph node status

–0.203

0.000

0.191

–0.056

–0.079

–0.33*

0.483**

1

0.112

0.204

0.015

Grade

0.164

0.111

0.275

–0.291

0.019

–0.085

0.342*

0.112

1

0.046

0.034

Metastases

–0.038

–0.211

0.247

0.077

0.142

0.108

0.098

0.204

0.046

1

0.119

Age

–0.184

0.049

–0.048

0.201

0.003

–0.081

–0.053

0.015

0.034

0.119

1

Values in bold are significant: * P ≤ 0.05; ** P ≤ 0.01.

(3/38, 7.9%, Table 3, Figure 2). Moderate level (4) of mCEA
expression was detected in 6 patients (6/38, 15.8%, Table
3). Statistical analysis did not show that mCEA expression
was significantly higher in tumor samples compared with
control patients (Figure 1). Positive expression of cyclin B1
in more than 50% of tumor cells was detected only in 6
tumor samples (6/38, 15.8%), while in 32 patients (32/38,
84.2%) the number of cyclin B1 positive cells was less than
50% (Table 3). In all 10 control cases the average number
of cyclin B1 positive cells was less than 30% (Table 3).
Statistical analysis showed significant differences in cyclin
B1 nucleus accumulation between tumor and control
tissues (F = 7.716, P < 0.05, Figure 1). Namely, cyclin
B1 expression was significantly higher in tumor than in
control samples (Figures 1 and 2).
3.3. VEGF and EPOR gene and protein expressions in
adenocarcinoma of the colon
Negative expression of EPOR was detected in 26 tumor
samples (26/38, 68.4%), while maximal positive expression,
scored as 6, was detected in 4 patients (4/38, 10.5%, Table
3). In control samples positive EPOR expression was
detected in 7 samples (7/10, 70%, Table 3). Similar to the
results for cyclin B1, statistical analysis showed significant
differences in EPOR expression between tumor and
control patients (P < 0.05, Figures 1 and 2). VEGF positive
protein expression was detected in 35 tumor tissue
samples (35/38, 92.1%, Table 3). Eight control samples
were negative for VEGF protein expression and had a
score of 1 (8/10, 80%, Table 3). The VEGF protein levels

were significantly higher in tumor samples than in control
samples (Figure 2). Statistical analysis showed that VEGF
gene expression was significantly higher in tumor than in
control samples (Figure 3). In contrast, EPO and EPOR
genes were expressed only in traces in tumor and control
samples (not shown).
4. Discussion
The presented findings showed that cyclin B1, EPOR, and
VEGF gene and protein expressions were significantly
higher in tumor than in control samples, while
E-cadherin expression was significantly decreased in
tumor samples, accompanied by positive correlation with
mCEA. Significant positive correlation characterized the
relationship between tumor size and cyclin B1 and that
between tumor grade and lymph node status. Positive
correlation was also observed between E-cadherin and
mCEA expression. Cyclin B1 and VEGF gene and protein
expressions were significantly increased in tumor samples
in comparison with their expressions in control patients.
The main role of E-cadherin in the process of normal
tissue development was verified with the appearance of
lethality in E-cadherin gene knockout mice at an early
stage during embryogenesis (20). Dysregulation of
E-cadherin expression was essential in the development
of neoplastic tissue, normal growth, loss of differentiation,
and increased cell proliferation related to invasive
behavior (6). It was shown that invasive behavior and the
appearance of metastasis in breast and bladder cancer
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Table 3. E-cadherin, mCEA, cyclin B1, VEGF, and EPOR expression in tumors and controls.
E-cadherin expression in tumors

E-cadherin expression in controls

0

5 (13.2%)

0

2

3 (7.9%)

0

3

4 (10.5%)

1 (10%)

4

9 (23.7%)

0

5

6 (15.8%)

3 (30%)

6

11 (28.9%)

6 (60%)

E-cadherin (tumors)
E-cadherin (controls)

8/38 (21.1%)

+

30/38 (78.9%)

–

0/5

+

10/10 (100%)

mCEA expression in tumors

mCEA expression in controls

0

0

0

2

0

0

3

3 (7.9%)

0

4

6 (15.8%)

4 (40%)

5

10 (26.3%)

4 (40%)

6

19 (50%)

2 (20%)

mCEA (tumors)
mCEA (controls)

–

0

+

38/38 (100%)

–

0/10

+

10/10 (100%)

EPOR expression in tumors

EPOR expression in controls

0

16 (42.2%)

0

2

10 (26.3%)

3 (30%)

3

4 (10.5%)

2 (20%)

4

3 (7.9%)

0

5

1 (2.6%)

2 (20%)

6

4 (10.5%)

3 (30%)

EPOR (tumors)
EPOR (controls)
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–

–

26/38 (68.4%)

+

12/38 (31.6%)

–

3/10 (30%)

+

7/10 (70%)

Cyclin B1 expression in tumors

Cyclin B1 expression in controls

≤50%

32 (84.2%)

10 (100%)

>50%

6 (15.8%)

0

VEGF expression in tumors

VEGF expression in controls

0

0

0

1

3 (7.9%)

8/10 (80%)

2

20 (52.6%)

2/10 (80%)

3

15 (39.5%)

0
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50

b

45
40

Adenocarcinoma

35

Control

30
25
20
15
10

c

a

d

5
0

E-cadherin

mCEA

Cyclin B1

EPOR

VEGF

Figure 1. Immunohistochemical expression of E-cadherin,
mCEA, cyclin B1, VEGF, and EPOR in colorectal adenocarcinoma
and controls. Control vs. adenocarcinoma of the colon: a)
E-cadherin (P < 0.05); b) Cyclin B1 (P < 0.05); c) EPOR (P <
0.05); d) VEGF (P < 0.01).

were associated with decreased expression of E-cadherin
(21,22). Our results are in agreement with these studies
because E-cadherin levels were significantly higher in
healthy controls than in tumor samples.
The mCEA levels in the serum of patients with
colorectal, gastric, pancreatic, lung, and breast carcinoma
were increased compared with those in the serum of
healthy controls (23). In the same study it was confirmed
that increased levels of serum mCEA showed 100%
sensitivity in differentiating metastatic liver disease from
colorectal cancer. Our results also demonstrated that
mCEA expression was higher in tumor samples than in
control ones. Moreover, serum concentrations of mCEA
were higher in patients with well-differentiated tumors
than in patients with poorly differentiated colon cancers
(24). Our results showed a positive, but not significant,
correlation between mCEA and tumor grade.
During the process of tumor growth, the lack of blood
supply created a hypoxic environment that induced the
release of hypoxia inducible factor-1 (HIF-1) to stimulate
angiogenesis by activating VEGF expression (25,26). Two
studies confirmed that high levels of VEGF expression
indicated poor prognosis in patients with colorectal cancer,
invasive tumor behavior with increased rates of vascularlymphatic and lymph node metastasis, and increased
incidence of distant metastasis (27,28). The results of the
present study also confirmed significantly higher levels of
VEGF gene and protein expressions in tumor samples of
colon adenocarcinoma than in control samples.
EPO and EPOR are expressed in numerous normal
nonhematopoietic cells as well as in cancer tissues,
especially at the surface of endothelial cells and various
solid tumors (10,12). EPO, EPOR, and VEGF play a key

role in the process of neoangiogenesis, supporting survival
of hypoxic cancer cells and tumor growth. Lee et al. (29)
showed that higher expression of VEGF and EPO were
associated with resistance to treatment, increased tumor
aggressiveness, and poor prognosis in patients with cancer.
In our study EPOR protein expression was significantly
higher in tumor samples than in control ones, but EPO
gene expression was found only in traces. This could be
related to the small invasiveness of the tumor and the
absence of a hypoxic state.
Despite significant progress, the role of E-cadherin,
mCEA, cyclin B1, and VEGF in colorectal cancer cells
remains unclear, especially in association with EPO and
EPOR expression. This is the first immunohistochemical
study to report E-cadherin, mCEA, cyclin B1, VEGF,
and EPOR expressions and their correlations with
clinicopathological factors in colorectal adenocarcinoma.
The present findings showed that cyclin B1 and VEGF
expressions were significantly elevated in tumor samples,
and E-cadherin expression was significantly decreased in
tumor samples and positively correlated with mCEA. A
significant positive correlation was found between cyclin
B1 and tumor size, tumor size and grade, and tumor size
and lymph node status. Since our study was carried out
for 1 year, we could not reach a conclusion about the
prognostic significance of the studied markers. However,
decreased expression of EPO and EPOR, increased VEGF
and cyclin B1 expression, and predominant moderate
differentiation of the tumor could suggest a low level of
aggressiveness, good prognosis, and long period of patient
survival. Observation of the same patient population for
an extended period could give valuable information about
the relationship between these factors and survival.
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Figure 2. Specific pattern of immunohistochemical expression of E-cadherin, mCEA, cyclin B1, VEGF, and EPOR in colorectal adenocarcinoma
and controls. Note the strong membranous deposition of E-cadherin in control cells (a) in contrast to colorectal cancer cells (b). mCEA showed
strong immunoreactivity in colorectal cancer cells (d) in comparison with control cells (c). Cyclin B1 expressed significantly higher in colorectal
cancer cells (f) in comparison with control cells (e). EPOR showed moderate membranous and partly perinuclear staining in colorectal cancer
cells (h) in comparison with its decreased expression in control cells (g). VEGF immunoreactivity was significantly higher in tumor cells (j) in
comparison with control tissue sections (i). Magnification: 20× (a, b, c, d, g, h, i, and j); 40× (e and f).
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VEGF/β-actin

0.100
0.075
0.050
0.025
0.000

Normal

Tissue

Tumor

Figure 3. VEGF gene expression in colorectal adenocarcinoma
tissue samples and neighboring healthy tissues (controls). Tumor
samples vs. controls: * P < 0.05.
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